Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03905603 · ClinicalTrials.gov registry record · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
A Early Phase 1 study of Polycystic Ovary Syndrome, sponsored by University of Virginia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 144
- Enrollment target
- 1
- Study location
NCT03905603: Recruiting Early Phase 1 study of Polycystic Ovary Syndrome, sponsored by University of Virginia.
NCT03905603 is a Early Phase 1 study of Polycystic Ovary Syndrome that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 144 participants, below the 17,253-participant average among 30 other Polycystic Ovary Syndrome trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03905603, a Early Phase 1 study of Polycystic Ovary Syndrome, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 144 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the study is to determine the relative contributions of four established predictors of hyperandrogenism (luteinizing hormone \[LH\] secretion, ovarian response to recombinant human chorionic gonadotropin \[r-hCG\] administration, adrenal response to adrenocorticotropic hormone \[ACTH\] administration, and hyperinsulinemia) in older vs. young women with Polycystic Ovary Syndrome (PCOS) in a cross-sectional, physiological study. The investigators hypothesize that hyperinsulinemia is a stronger independent predictor of free testosterone (T) in older reproductive aged (vs. young) women with PCOS.
Conditions Studied
Interventions
- DRUG ACTH
- DRUG rhCG
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2019-10-08 |
| Est. Completion | 2026-05-01 |
| Phase | Early Phase 1 |
What NCT03905603 shows while recruiting
NCT03905603 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 17,253-participant average among 30 other Polycystic Ovary Syndrome trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Polycystic Ovary Syndrome appearing as the primary indexed condition, and to 2 interventions - of which ACTH is the first listed.
NCT03905603 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT03905603 about?
NCT03905603 is a clinical study titled "Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS". The objective of the study is to determine the relative contributions of four established predictors of hyperandrogenism (luteinizing hormone \[LH\] secretion, ovarian response to recombinant human chorionic gonadotropin \[r-hCG\] administration, adrenal response to adrenocorticotropic hormone \[ACT...
What is the current status of trial NCT03905603?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 144 participants. The study started on 2019-10-08. Estimated completion is 2026-05-01.
What conditions does trial NCT03905603 study?
This clinical trial studies the following conditions: Polycystic Ovary Syndrome.
What interventions are being tested in trial NCT03905603?
The interventions under investigation include: ACTH (DRUG), rhCG (DRUG).
Who is sponsoring clinical trial NCT03905603?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03905603 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycystic Ovary Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03905603's enrollment target sits among peer trials
144 8th of 30 higher than 23 of 30 other Polycystic Ovary Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Polycystic Ovary Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?
RECRUITING · Early Phase 1
-
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
RECRUITING · Early Phase 1
-
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
RECRUITING · Early Phase 1
-
Combined Oral Contraceptive Pill and Resistance Starch
RECRUITING · Phase 2
-
The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
RECRUITING · NA
-
Apple Women's Health Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT04215809 · 144 participants · Phase 1
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI